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ABSTRACT 
In continuing our efforts to identify small molecules able to disrupt PA-PB1 subunits interaction of 
influenza virus (Flu) RNA-dependent RNA polymerase, this paper was devoted to the optimization 
of a dihydrotriazolopyrimidine derivative, previously identified through a structure-based drug 
discovery. The structure modifications performed around the bicyclic core led to the identification 
of compounds endowed with both the ability to disrupt PA-PB1 subunits interaction and anti-Flu 
activity with no cytotoxicity. Very interesting results were obtained with the hybrid molecules 36 
and 37, designed by merging some peculiar structural features known to impart PA-PB1 interaction 
inhibition, with compound 36 that emerged as the most potent PA-PB1 interaction inhibitor (IC50 of 
1.1 µM) among all the small molecules reported so far. Calculations showed a very favored H-
bonding between the 2-amidic carbonyl of 36 and Q408, which seems to justify its potent ability to 
interfere with the polymerase subunits interaction.  
 
INTRODUCTION 
Influenza is a highly contagious, acute, febrile, respiratory illness. Only two classes of drugs are 
currently available to treat influenza infections, i.e., M2 ion channel inhibitors and neuraminidase 
inhibitors. Unfortunately, their clinical use is limited by serious side effects, low efficacy, and the 
emergence of resistant virus variants.1−3 Because of these issues, the M2 ion channel inhibitors are 
no longer even recommended;4 thus, the neuraminidase inhibitors, such as oseltamivir, represent the 
firstline therapy, although their widespread use has been reported to favor the emergence of 
resistant viral strains.5 Clearly, new anti-influenza virus (Flu) strategies based on alternative 
mechanisms of action are strongly needed. Along this line, we have chosen the viral RNA-
dependent RNA polymerase (RdRP) as a valid antiviral target since it is essential for virus 
replication and plays an important role in the viral pathogenesis by contributing to the host-
adaptation process. In addition, it is highly conserved among FluA, -B, and -C, and its mechanism 
of action significantly differs from that of the human RNA polymerases.6 Flu RdRP is a complex of 
three subunits, polymerase acidic protein (PA), polymerase basic protein 1 (PB1), and polymerase 
basic protein 2 (PB2), whose correct assembly into functional RdRP is an essential step for Flu 
RNA synthesis and replication. The inhibition of protein−protein interactions (PPIs) between the 
subunits of the viral RNA polymerase represents an attractive as well as challenging strategy that 
could expand the narrow target spectrum of anti-Flu drugs.7−9 Previous studies have revealed that 
the N-terminal and the C-terminal regions of PB1 interact with the C-terminus of PA 10−14 and the 
N-terminus of PB2, 11,15 respectively. While no small molecule targeting the PB1−PB2 interaction 
is known, with only a few short peptides reported for this activity, 16,17 various small molecules that 
are able to disrupt the interactions between the PA and PB1 subunits have emerged during the past 
3 years.18−25 Their PPI inhibitory activity correlated to the inhibition of viral RdRP activity and of 
virus replication in a cellular context, thus validating this antiviral strategy. Different approaches 
led to identification of the PA−PB1 small molecule inhibitors reported so far (Figure 1). 
Nitrobenzofurazan derivatives have emerged from a biochemical ELISA-based screening,21 which 
was followed by an optimization study that gave compound 123 as one of the most active. drug 
discovery (SBDD) strategy. In particular, compounds 3 (benzbromarone)19 and 4 (diclazuril)19 came 
from an in silico screening performed on a database of 4000 drugs, while by screening 3 million 
small molecules we have discovered the promising hit compounds 5−8.18 A successive round of 
optimization performed on compounds 6 and 7 led to the improved derivatives 9 22 and 10 22 
(Figure 1), whose anti-Flu activity also encompassed a panel of clinical isolates of FluA, including 
an oseltamivir-resistant strain, and of FluB, without showing appreciable cytotoxicity. In this study, 
with the aim of broadening the class of PA−PB1 interaction inhibitors as alternative anti-Flu agents, 
the optimization of the dihydrotriazolopyrimidine derivative 8 is reported. On the other hand, 
anthracene derivative 220 was discovered by serendipity. However, the largest number of PA−PB1 
interaction inhibitors was identified through a structure-based. 
 
DESIGN OF TRIAZOLOPYRIMIDINE DERIVATIVES  
Among the hit compounds previously identified, the dihydrotriazolopyrimidine derivative 8 showed 
a weak PA-PB1 interaction inhibitory activity (IC50 = 170.6 µM) and no antiviral activity up to 100 
µM, but the lack of any cytotoxic effect (CC50 > 250 µM in MDCK cells)
9 made it worthy of further 
investigation. The structural modifications were initially focused on the benzamide moiety at the C-
2 position (Table 1). The methoxy group was run into ortho and meta positions (compounds 11 and 
12) and an analogous set of derivatives was synthesized having a fluorine atom (compounds 13-15). 
Since in these two series of compounds the para derivatives were slightly more active than the other 
isomers, the successive substituents were placed only at the para position, synthesizing compounds 
16-24. Additional derivatives were 25, characterized by a bicyclic aromatic ring, 26, devoid of any 
substituent on the phenyl ring, and 27, where an ethyl chain was inserted between the phenyl ring 
and the amide moiety. Since some difficulties were encountered with the purification of this first 
series of derivatives, the 4,7-dihydro-[1,2,4]triazolo[1,5-a]pyrimidine nucleus was oxidized leading 
to more manageable aromatic compounds. Derivatives 28-30 were synthesized using the phenyl, the 
p-methoxyphenyl, and p-propoxyphenyl rings, respectively, as C-2 substituents.  
Previous computational studies indicated that a more linear shape of the compounds could increase 
the inhibitory effect.15 Moreover, the alignment of the 1,2,4-triazolo[1,5-a]pyrimidine derivative 28 
to the recently published pharmacophore for PA-PB1 inhibitors15 (Figure 2, A and B), indicated that 
the 7-phenyl ring was not fitting any hydrophobic pharmacophoric point (green spheres in Figure 2) 
but, on the contrary, it was pointing towards polar atomic coordinates (red and blue spheres in 
Figure 2). In the light of the above considerations, we decided to further modify the central core by 
interchanging the methyl and the phenyl ring, synthesizing compounds 31-33. Figure 2C reports the 
alignment of 31 to the pharmacophore.  
Since the H-bond acceptor and H-bond donor pharmacophoric points underneath the amide group 
proved to be essential for pharmacophore definition,15 the presence of an inverse amide group 
linking the triazolopyrimidine core and the phenyl ring was studied by synthesizing the couple of 
positional isomers 34 and 35.  
Finally, as additional analogues of 8, hybrid molecules were designed by combining some of the 
structural features shown to confer PA-PB1 inhibitory activity.9,13,15 Among the planned molecules, 
the positional isomers 36 and 37 (Table 1) were synthesized by merging the 1,2,4-
triazolopyrimidine nucleus with the cycloheptathiophene-3-carboxamide core that characterizes the 
previous hit 7 (Figure 1). The two hybrid molecules were aligned to the pharmacophore, obtaining a 
good similarity both for polar and hydrophobic regions (Figure 3), with the 1,2,4-triazolopyrimidine 
nucleus being oriented in the lower hydrophobic region of the pharmacophore, in an opposite way 
to compounds 28 and 31 (Figure 2), to gain the better alignment of the polar regions. 
 
CHEMISTRY 
The synthesis of all the target compounds was accomplished through a carbodiimide-mediated 
coupling reaction by reacting the 2-amino and 2-carboxylic acid 1,2,4-triazolo[1,5-a]pyrimidine 
synthones with the appropriate benzoyl chlorides and amines, respectively. Although the 
triazolopyrimidines chemistry has been widely explored,26 very few reports were focused on the 
synthesis of 2-amino and 2-carboxylic acid 1,2,4-triazolo[1,5-a]-pyrimidine derivatives. Thus, the 
synthesis of the synthones 38, 41, 42, 45, and 47 required an in-depth study aimed to determine the 
best synthetic pathway and conditions to obtain the desired positional isomers in high yield. In 
Schemes 1 and 2, selected procedures among those reported in the literature or appositely setup are 
shown, while a thorough comparative study will be reported in due course. Synthone 38 27 was 
prepared as reported in the literature, by reacting 3,5-diamino-1,2,4-triazole with 
benzylideneacetone in DMF at reflux (Scheme 1). The same reaction was applied to prepare 
synthone 41 28 (Scheme 1), but adding Ac2O to the reaction mixture after the condensation 
completion, in order to protect the amino group in the successive oxidation step. The oxidation of 
compound 39 performed with N-bromosuccinimide (NBS) gave intermediate 40, which after acid 
hydrolysis gave the desired synthone 41. An analogous three-step procedure was planned to 
synthesize the unknown synthone 42 by reacting 3,5-diamino-1,2,4-triazole with phenyl 1-propenyl 
ketone in DMF at reflux (Scheme 1). Fortunately, the reaction furnished directly the aromatic 
compound 42. The reaction of synthones 38, 41, and 42 with the appropriate benzoyl chloride, 
performed in pyridine, furnished the target compounds 8 and 11−33. All the 4,7-
dihydrotriazolopyrimidine derivatives were purified by crystallization from EtOH, since the 
compounds undergwent an extensive transformation to a main unidentified product when column 
chromatography was used as purification method.  
Similarly to the preparation of synthones 41 and 42, the synthesis of triazolopyrimidine-2-
carboxylic acids 45 and 47 was accomplished by reacting ethyl 5-amino-1,2,4-triazole-3-
carboxylate 29 with benzylideneacetone and phenyl 1-propenyl ketone, respectively, in DMF at 
reflux (Scheme 2). Using 3-amino-1,2,4-triazole-5-carboxylic acid as starting material, the reaction 
furnished only decarboxylated triazolopyrimidine scaffolds. In agreement with what has been 
described above, the reaction with benzylideneacetone gave the saturated compound 43, which was 
then oxidized with NBS in EtOH at reflux in the presence of AcONa, to give 44. On the other hand, 
the reaction with phenyl 1-propenyl ketone provided directly the aromatic intermediate 46. Ethyl 
triazolopyrimidine esters 44 and 46 were then hydrolyzed under basic conditions, furnishing the key 
acids 45 and 47. The carbodiimide-mediated coupling reaction was then carried out by reacting the 
1,2,4-triazolopyrimidine-2-carbonyl chloride, prepared from the acids 45 and 47 by reaction with 
oxalyl chloride in CH2Cl2, with 2-amino-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-
carboxamide or aniline, in CH2Cl2 in the presence of DIPEA, to give the target compounds 34−37. 
 
RESULTS AND DISCUSSION 
Hit compound 8 (compound 31 in ref 18), previously tested as provided from the vendor, was 
synthesized and retested, giving comparable results in terms of PA−PB1 interaction inhibitory 
activity (IC50 = 153 μM) and maintaining the same profile of antiviral activity and cytotoxicity. The 
in-house synthesized 8 was then used as comparative compound in all successive studies.  
The whole set of derivatives was evaluated for the ability to inhibit the physical interaction 
between PA and PB1 subunits by ELISA, including the PB1(1−15)−Tat peptide 30 as a positive 
control. In parallel, for all the synthesized compounds, the antiviral activity was tested by plaque 
reduction assay (PRA) in Mardin−Darby canine kidney (MDCK) cells infected with a reference 
FluA virus, the A/PR/8/34 strain. Ribavirin (RBV), a known broad-spectrum inhibitor of RNA 
viruses polymerase,31 was included as a positive control of inhibition, exhibiting EC50 = 10 μM. To 
exclude that the observed antiviral activities could be due to toxic effects in the target cells, all the 
synthesized compounds were tested by MTT assays in two cell lines, i.e., MDCK and human 
embryonic kidney (HEK) 293T. The antiviral activity and toxicity data for the tested compounds 
are reported in Table 1.  
As to what impacts the modifications made on the phenyl ring at the C-2 position of the 
dihydrotriazolopyrimidine core, the shifting of the methoxy group from para (compound 8) to meta 
(compound 12) and ortho (compound 11) positions decreased the PA−PB1 interaction inhibitory 
activity. The same behavior was observed for the fluoro analogues 13−15. Among the various para-
substituted derivatives, compounds 16−18 were more active than hit 8, but only for p-propoxy 
derivative 16 did the ability to inhibit the PA−PB1 interaction perfectly translate to anti-Flu activity 
in a cellular context, with EC50 = 47 μM. On the other hand, compounds 19, 21, and 25 inhibited the 
viral growth but did not interfere with the PA−PB1 complex formation. For these compounds, all 
characterized by a bulky substituent at the C-2 position, an alternative mechanism of action might 
be postulated, or simply the antiviral activity could be due to a certain toxicity.  
The aromatic triazolopyrimidine compounds 28−30 were all devoid of activity against the 
PA−PB1 interaction, thus making them less suitable than their 4,7-dihydrotriazolopyrimidine 
counterparts (compounds 26, 8, and 16). The Fingerprints for Ligands and Proteins (FLAP) binding 
poses evaluated in silico for compound 26 and its aromatic analogue 28 were very similar, with the 
heterocyclic and heteroaromatic cores interacting with W706 (Figure 4). However, compound 28, 
due to its more linear shape, appears to match the hydrophobic field generated by W706 less 
efficiently than 26, and this difference might be responsible for the lower activity of the aromatic 
analogues.  
When in the aromatic scaffold the methyl and phenyl groups were interchanged (compounds 
31−33), the PA−PB1 inhibitory activity was restored, with compound 31 exhibiting a good IC50 
value of 26 μM, perfectly comparable to that obtained in inhibiting the vral replication (EC50 = 25 
μM). The ability of compound 31 to interfere with PA−PB1 complex markedly decreased when the 
C-2 amide linker was inverted, as in compound 35, which however maintained the antiviral activity.  
Definitely, the most exciting result in this study was achieved with the hybrid molecules 36 
and 37, designed by merging some peculiar structural features of the PA−PB1 interaction inhibitors 
developed by us. With an IC50 = 1.1 μM, compound 36 emerged as the most potent PA−PB1 
inhibitor within this series of compounds as well as among all the small molecules published so far. 
The other hybrid molecule 37, although endowed with a lower ability to interfere with PA−PB1 
complex formation (IC50 = 28 μM), emerged as the best in inhibiting the viral growth (EC50 = 8.0 
μM). Structurally, the two molecules differ only in opposite positions of the substituents on the 
triazolopyrimidine core, with the 5-methyl group and 7-phenyl ring being the most suitable 
substitution pattern for PA−PB1 inhibition. To evaluate possible differences in the binding mode of 
compounds 36 and 37, their FLAP binding poses were analyzed (Figure 5). Both compounds orient 
the triazolopyrimidine ring toward the W706 residue of PA that defines the first hydrophobic 
pocket, to give an efficient π−π stacking. In addition, compound 37, due to its elongated shape, 
seems to be able to locate the phenyl ring into the second hydrophobic pocket of PA, defined by 
P710 and L666, and the cycloheptathiophene ring into the third hydrophobic pocket defined by 
L640, V636, and W619, according to the cavity description by Liu and co-workers33 (Figure 5A). 
This binding mode is comparable to that previously observed for compound 924 (data not shown). 
On the other hand, compound 36 seems to be shifted toward the opposite side of the cavity, thus 
matching only the first hydrophobic region (Figure 5B). Changing the perspective (Figure 5C,D), 
we can notice that, based on this model, the shift for compound 36 is due to a favored H-bonding 
between its 2-amidic carbonyl group and Q408, according to the FLAP GRID fields analysis. In our 
previous studies, the interactions with W706 and with the second hydrophobic pocket in proximity 
of P710 were usually detected for the most active compounds; the achievement of more active 
derivatives designed to optimize these hydrophobic interactions validated the hypothesis about this 
favorable binding mode.22 On the contrary, compound 36 emerges as the first compound within our 
series of derivatives for which an interaction with Q408 seems to occur. Although these findings 
need to be further investigated, it is known that Q408 is a key residue for PB1 binding through H-
bonding, and this might be the reason for the surprisingly potent activity. The interaction with Q408 
has been recently hypothesized also for other PA−PB1 inhibitors, although their inhibitory effect 
was lower than that of compound 36.34 From the comparison of the spatial dispositions of the two 
amidic carbonyl groups in compounds 36 and 37 in Figures 5 with the ones in Figure 3, minor 
differences emerge. These differences are induced by the interaction with the protein structure, and 
this is a demonstration that combining a pharmacophore approach with a structure-based approach, 
when possible, represents a suitable strategy for pharmacophore refinement.  
Compounds 16, 31, 36, and 37, endowed with the best ability to inhibit both PA−PB1 
interaction and viral growth, were further characterized. First, we investigated their ability to 
interfere with the catalytic activity of FluA RdRP in a cellular context by minireplicon assays 
performed in transfected HEK 293T cells. As shown in Table 2, for all the compounds the ability to 
disrupt the PA−PB1 interaction in vitro correlated well with the polymerase inhibitory activity, with 
the best compounds 36 and 37 showing EC50 values of 12 and 16 μM, respectively, comparable to 
that of the reference compound RBV (EC50 = 18 μM). We then tested the ability of the best 
compound 36 to interfere with the physical interaction between PA and PB1 in a cellular context. 
To this end, we investigated whether the compound could affect PA−PB1 binding in the cell 
cytoplasm and consequently block the intranuclear translocation of PA, which requires formation of 
a PA−PB1 complex,32 while PB2 enters the cell nucleus independently. Thus, we transfected HEK 
293T cells with plasmids expressing PB1, PB2, and a PA−GFP fusion protein and analyzed the 
intracellular localization of PA−GFP in the presence or absence of compound 36 (or DMSO as a 
control). As previously shown,32 individually expressed PA−GFP was largely cytoplasmic, while 
coexpression of PA−GFP with PB1 and PB2 resulted in marked nuclear accumulation of PA 
(Figure 6). Treatment of PA−PB1−PB2-coexpressing cells with compound 36 reduced PA nuclear 
localization, while DMSO had no effect (Figure 6). 
Finally, the antiviral effects of compounds 16, 31, 36, and 37 against a number of strains of 
FluA of both HIN1 and H3N2 subtypes, including an oseltamivir-resistant clinical isolate 
(A/Parma/24/09), and three strains of FluB were also evaluated (Table 3). All the compounds 
showed an interesting antiviral activity against the whole panel of Flu strains, perfectly comparable 
to that measured against the A/PR/8/34 strain. Compound 37 confirmed its anti-Flu potency by 
exhibiting the best antiviral activity, with EC50 = 5 μM against both the FluA oseltamivir-resistant 
clinical isolate and Flu B/Lee/40 strain. At this stage, the absorption, distribution, metabolism, and 
excretion (ADME) profile was preliminarily determined to assess the drug-like properties of these 
new small molecules. Toward this end, for the same set of compounds, 16, 31, 36, and 37, along 
with the hit 8, the solubility (equilibrium solubility in phosphate buffer at pH 7.4), permeability 
(parallel artificial membrane permeation assay (PAMPA)), and human liver microsome (HLM) 
metabolic stability were experimentally determined. Concerning the solubility, compound 8 showed 
the highest equilibrium solubility (13 μg/mL), followed by compounds 16 and 31 (5 μg/mL) and 
then by compounds 36 and 37, which showed very low solubility (<1 μg/mL). Because of this issue, 
we could not clearly estimate the cell permeability of compound 37. Based on the PAMPA, all the 
tested compounds showed a medium/high permeability (data are reported in the Experimental 
Section) and a percentage of compound trapped into the membrane ranging from 41 to 57%, with 
the exception of 31, the sole compound not retained by the lipid membrane. Notably, all the studied 
PA−PB1 inhibitors were metabolically stable in HLM, since no metabolites were detected after 30 
min exposure to cytochrome metabolism. Altogether, these studies suggested that the 
triazolopyrimidine-based compounds are endowed with an adequate ADME profile for a drug-
discovery phase, even though the most promising antiviral derivatives 36 and 37 suffered from low 
solubility. Since these hybrid molecules are made of a triazolopyrimidine core merged to a 
cycloheptathiophene scaffold, we hypothesize that the latter may be responsible for the low 
solubility. Indeed, ADME studies performed on the previous cycloheptathiophene derivatives 7 and 
10 showed the same poor equilibrium solubility (<1 μg/mL) and a medium/high permeability, 
although they interacted almost entirely with the lipid membrane, hampering the enrichment of the 
acceptor phase. Thus, although compound 36 is characterized by a promising ADME profile, 
further modifications of the cycloheptathiophene moiety will be required to achieve the best 
compromise between solubility and cell permeability. 
 
 
CONCLUSIONS 
The limited therapeutic options against Flu infection along with the drug resistance issue make 
imperative the search for next generation agents. Although the inhibition of viral polymerases is a 
common approach in the identification of antiviral drugs, the development of compounds able to 
interfere with the correct assembly of viral polymerase complexes is an innovative strategy.35−38  
In this context, we have been recently interested in the inhibition of the interaction of Flu 
polymerase PA−PB1 subunits by small molecules. In the present work, starting from the 
dihydrotriazolopyrimidine hit 8, a weak PA−PB1 interaction inhibitor with no significant anti-Flu 
activity, and through a hit-to-lead optimization, novel potent inhibitors endowed with a broad anti-
Flu activity have been discovered. The best results were achieved with the hybrid molecules 36 and 
37, obtained by combining the herein developed triazolopyrimidine and the previously explored 
cycloheptathiophene scaffolds. With an IC50 = 1.1 μM, compound 36 exhibits a 150-fold higher 
activity than hit compound 8, definitely emerging as the most potent in the scenario of the PA−PB1 
small molecule inhibitors developed so far. This ability translates in a broad anti-Flu activity with 
no cytotoxicity. From this study, the triazolopyrimidine core emerges as very suitable to inhibit the 
physical interaction between PA and PB1 subunits, probably thanks to an efficient π−π staking 
interaction with W706 of the first hydrophobic pocket, as suggested by the FLAP poses. The 
computational studies also showed that the different binding mode of the various triazolopyrimidine 
derivatives is markedly influenced by the substituents at the C-5 and C-7 positions but mainly by 
the group placed at the C-2 position. While the 2-cycloheptanethiophene moiety is definitely able to 
ensure potent activity, a wider exploration of the C-2 position is strongly required, also to meet the 
need for compounds with an improved ADME profile. The design of new drug-like analogues, also 
based on hydrophilic interactions while decreasing unnecessary hydrophobic moieties, is also 
supported by the peculiar ability of the potent compound 36 to establish a very favored H-bonding 
with Q408.  
During the final drafting of this manuscript, novel crystal structures of the influenza virus 
polymerase were published,39,40 thus opening new opportunities to refine the SBDD. 
 
EXPERIMENTAL SECTION 
Computational methods. The binding poses in the PA cavity were generated using the FLAP 
software (Molecular Discovery Ltd., UK; www.moldiscovery.com). Indeed, the FLAP approach41 
was previously used to identify inhibitors of the PA-PB1 complex by virtual screening18 and proved 
also to be useful to design more active compounds.22 The procedure has been extensively described 
elsewhere.22 As in the previous studies, the main cavity of the crystallographic structure of a large 
C-terminal fragment of PA (aa 257-716) (pdb code: 3CM8)14 was used as a template. A total of 50 
conformers for each ligand were generated to mimic the compound flexibility, and the most 
abundant protonation state predicted of each molecule was used, as predicted by MoKa.42 The 
probes used to generate the GRID Molecular Interaction Fields were H (shape), DRY (hydrophobic 
interactions), N1 (H-bond donor) and O (H-bond acceptor) interactions. The FLAP software was 
also used to align the selected compounds into the pharmacophore model. The pharmacophore 
generation using FLAPpharm algorithm43 was recently described.24 Here, the pharmacophore was 
used as a template to run the FLAP virtual screening module. 
Chemistry. All reactions were routinely checked by TLC on silica gel 60F254 (Merck) and 
visualized by using UV or iodine. Flash column chromatography separations were carried out on 
Merck silica gel 60 (mesh 230-400). Melting points were determined in capillary tubes (Büchi 
Electrothermal Mod. 9100) and are uncorrected. HRMS spectra were registered on Agilent 
Technologies 6540 UHD Accurate Mass Q-TOF LC/MS, HPLC 1290 Infinity. Purities of the 
compounds were determined by elemental analyses and the data for C, H, and N are within ± 0.4% 
of the theoretical values (purity of ≥95%). Elemental analyses were performed on a Fisons 
elemental analyzer, Model EA1108CHN. 1H NMR and 13C NMR spectra were recorded at 200 
MHz (Bruker Avance DPX-200) and 400 MHz (Bruker Avance DRX-400) using residual solvents 
such as chloroform (δ = 7.26) or dimethylsulfoxide (δ = 2.48) as an internal standard. Chemical 
shifts are given in ppm (δ) and the spectral data are consistent with the assigned structures. 
Reagents and solvents were purchased from common commercial suppliers and were used as such. 
After extraction, organic solutions were dried over anhydrous Na2SO4, filtered, and concentrated 
with a Büchi rotary evaporator at reduced pressure. Yields are of purified product and were not 
optimized. All starting materials were commercially available unless otherwise indicated.  
General procedure for carbodiimide formation (Method A). A solution of the appropriate 
synthones (1.0 equiv) in pyridine was added of the suitable benzoyl chloride (2.0 equiv). The 
reaction mixture was maintained at room temperature until no starting material was detected by 
TCL. After cooling, the reaction mixture was poured into ice/water, obtaining a precipitate which 
was filtered and purified as described below.  
Compounds 8 and 11-27 were prepared starting from synthone 3827 through Method A and purified 
by crystallization by EtOH.  
4-Methoxy-N-(5-methyl-7-phenyl-4,7-dihydro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)benzamide 
(8). Yield, 100%. Light yellow crystals, mp 228-230 °C; 1H NMR (DMSO-d6)  1.95 (s, 3H, CH3), 
3.75 (s, 3H, OCH3), 4.50 and 6.00 (s, each 1H, CH), 6.95 (d, J = 7.9 Hz, 2H, aromatic CH), 7.20-
7.35 (m, 5 H, aromatic CH), 7.85 (d, J = 7.9 Hz, 2H, aromatic CH), 9.50 (s, 1H, NH), 10.25 (s, 1H, 
NHCO); 13C NMR (DMSO-d6)  18.7, 55.8, 59.8, 96.1, 113.9, 126.3, 127.2, 128.2, 128.9, 130.1, 
131.9, 143.0, 148.9, 154.3, 162.4, 164.9. HRMS: m/z calcd for C20H19N5O2 362.1572 and 
C20H19N5O2 H2O 380.1678 (M+H
+), found 362.1619 and 380.1724. Anal. (C20H19N5O2 · 0.2 H2O) 
C, H, N.  
2-Methoxy-N-(5-methyl-7-phenyl-4,7-dihydro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)benzamide 
(11). Yield, 94%. Light yellow crystals, mp 154-156 °C; 1H NMR (DMSO-d6)  1.95 (s, 3H, CH3), 
3.75 (s, 3H, OCH3), 4.50 and 5.90 (s, each 1H, CH), 6.95 (t, J = 7.4 Hz, 1H, aromatic CH), 7.10 (d, 
J = 8.2 Hz, 1H, aromatic CH), 7.20-7.35 (m, 5H, aromatic CH), 7.45 (t, J = 7.4 Hz, 1H, aromatic 
CH), 7.55-7.65 (m, 1H, aromatic CH), 9.50 (s, 1H, NH), 10.00 (s, 1H, NHCO). Anal. (C20H19N5O2 · 
0.3 H2O) C, H, N.  
3-Methoxy-N-(5-methyl-7-phenyl-4,7-dihydro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)benzamide 
(12). Yield, 75%. Light yellow crystals, mp 159-161 °C; 1H NMR (DMSO-d6)  1.95 (s, 3H, CH3), 
3.75 (s, 3H, OCH3), 4.50 and 5.90 (s, each 1H, CH), 7.00-7.45 (m, 9H, aromatic CH), 9.50 (s, 1H, 
NH), 10.45 (s, 1H, NHCO). Anal. (C20H19N5O2 · 0.2 H2O) C, H, N.  
4-Fluoro-N-(5-methyl-7-phenyl-4,7-dihydro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)benzamide 
(13). Yield, 100%. Light yellow crystals, mp 253-255 °C; 1H NMR (DMSO-d6)  1.95 (s, 3H, 
CH3), 4.50 and 6.00 (s, each 1H, CH), 7.20-7.35 (m, 7H, aromatic CH), 7.90-7.95 (m, 2H, aromatic 
CH), 9.50 (s, 1H, NH), 10.50 (s, 1H, NHCO). Anal. (C19H16FN5O · 0.4 H2O) C, H, N.  
3-Fluoro-N-(5-methyl-7-phenyl-4,7-dihydro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)benzamide 
(14). Yield, 100%. Light yellow crystals, mp 248-250 °C; 1H NMR (DMSO-d6)  1.95 (s, 3H, 
CH3), 4.50 and 6.00 (s, each 1H, CH), 7.20-7.35 (m, 7H, aromatic CH), 7.45-7.55 (m, 2H, aromatic 
CH), 9.50 (s, 1H, NH), 10.60 (s, 1H, NHCO). Anal. (C19H16FN5O · 0.5 H2O) C, H, N. 
2-Fluoro-N-(5-methyl-7-phenyl-4,7-dihydro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)benzamide 
(15). Yield, 100%. Light yellow crystals, mp 139-141 °C; 1H NMR (DMSO-d6)  1.95 (s, 3H, 
CH3), 4.50 and 5.90 (s, each 1H, CH), 7.15-7.35 (m, 7H, aromatic CH), 7.45-7.55 (m, 2H, aromatic 
CH), 9.50 (s, 1H, NH), 10.50 (s, 1H, NHCO). Anal. (C19H16FN5O · 0.3 H2O) C, H, N.  
N-(5-Methyl-7-phenyl-4,7-dihydro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)-4-propoxybenzamide 
(16). Yield, 100%. Light yellow crystals, mp 235-237 °C; 1H NMR (DMSO-d6)  0.95 (t, J = 7.0 
Hz, 3H, CH2CH3), 1.70 (sex, J = 7.0 Hz, 2H, CH2CH3), 1.90 (s, 3H, CH3), 3.95 (t, J = 7.0 Hz, 2H, 
OCH2), 4.50 and 5.95 (s, each 1H, CH), 6.90 (d, J = 8.7 Hz, 2H, aromatic CH), 7.20-7.35 (m, 5H, 
aromatic CH), 7.80 (d, J = 8.7 Hz, 2H, aromatic CH), 9.50 (s, 1H, NH), 10.25 (s, 1H, NHCO). 
Anal. (C22H23N5O2 · 0.2 H2O) C, H, N. 
4-Butoxy-N-(5-methyl-7-phenyl-4,7-dihydro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)benzamide 
(17). Yield, 45%. White crystals, mp 249-251 °C; 1H NMR (DMSO-d6)  0.90 (t, J = 7.4 Hz, 3H, 
CH2CH3), 1.40 (sex, J = 7.0 Hz, 2H, CH2CH3), 1.70 (quin, J = 6.5 Hz, 2H, CH2CH2CH3), 1.85 (s, 
3H, CH3), 4.00 (t, J = 6.5 Hz, 2H, OCH2), 4.50 and 5.95 (s, each 1H, CH), 6.90 (d, J = 8.5 Hz, 2H, 
aromatic CH), 7.20-7.35 (m, 5H, aromatic CH), 7.80 (d, J = 8.5 Hz, 2H, aromatic CH), 9.50 (s, 1H, 
NH), 10.25 (s, 1H, NHCO). Anal. (C23H25N5O2 · 0.2 H2O) C, H, N.  
4-Butyl-N-(5-methyl-7-phenyl-4,7-dihydro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)benzamide (18). 
Yield, 51%. White crystals, mp 261-263 °C; 1H NMR (DMSO-d6)  0.90 (t, J = 7.4 Hz, 3H, 
CH2CH3), 1.40 (sex, J = 7.4 Hz, 2H, CH2CH3), 1.70 (quin, J = 7.4 Hz, 2H, CH2CH2CH3), 1.85 (s, 
3H, CH3), 2.55 (t, J = 7.4 Hz, 2H, CCH2), 4.50 and 5.95 (s, each 1H, CH), 7.20-7.25 (m, 5H, 
aromatic CH), 7.30-7.35 (m, 2H, aromatic CH), 7.80 (d, J = 8.1 Hz, 2H, aromatic CH), 9.50 (s, 1H, 
NH), 10.25 (s, 1H, NHCO). Anal. (C23H25N5O · 0.4 H2O) C, H, N.  
N-(5-Methyl-7-phenyl-4,7-dihydro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)-4-phenoxybenzamide 
(19). Yield, 84%. White crystals, mp 217-219 °C; 1H NMR (DMSO-d6)  1.95 (s, 3H, CH3), 4.50 
and 5.90 (s, each 1H, CH), 6.90-7.40 (m, 12 H, aromatic CH), 7.90 (d, J = 8.4 Hz, 2H, aromatic 
CH), 9.55 (s, 1H, NH), 10.40 (s, 1H, NHCO). Anal. (C25H21N5O2 · 0.3 H2O) C, H, N. 
4-Isopropoxy-N-(5-methyl-7-phenyl-4,7-dihydro[1,2,4]triazolo[1,5-a]pyrimidin-2-
yl)benzamide (20). Yield, 20%. White crystals, mp 229-231 °C; 1H NMR (DMSO-d6)  1.20 (d, J 
= 6.0 Hz, 6H, CH(CH3)2), 1.80 (s, 3H, CH3), 4.50 (s, 1H, CH), 4.60 (quin, J = 6.0 Hz, 1H, 
CH(CH3)2), 5.85 (s, 1H, CH), 6.90 (d, J = 8.7 Hz, 2H, aromatic CH), 7.20-7.35 (m, 5H, aromatic 
CH), 7.80 (d, J = 8.7 Hz, 2H, aromatic CH), 9.55 (s, 1H, NH), 10.25 (s, 1H, NHCO). Anal. 
(C22H23N5O2 · 0.2 H2O) C, H, N.  
N-(5-Methyl-7-phenyl-4,7-dihydro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)biphenyl-4-
carboxamide (21). Yield, 56%. Light brown crystals, mp 257-259 °C; 1H NMR (DMSO-d6)  1.85 
(s, 3H, CH3), 4.50 and 5.90 (s, each 1H, CH), 7.20-7.45 (m, 8H, aromatic CH), 7.60-7.70 (m, 4H, 
aromatic CH), 7.90 (d, J = 8.4 Hz, 2H, aromatic CH), 9.55 (s, 1H, NH), 10.50 (s, 1H, NHCO). 
Anal. (C25H21N5O · 0.3 H2O) C, H, N.  
4-Ethoxy-N-(5-methyl-7-phenyl-4,7-dihydro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)benzamide 
(22). Yield, 36%. Pink crystals, mp 227 °C (dec.); 1H NMR (DMSO-d6)  1.25 (t, J = 7.0 Hz, 3H, 
CH2CH3), 1.80 (s, 3H, CH3), 4.00 (q, J = 7.0 Hz, 2H, CH2CH3), 4.50 and 5.90 (s, each 1H, CH), 
6.90 (d, J = 8.8 Hz, 2H, aromatic CH), 7.20-7.30 (m, 5H, aromatic CH), 7.80 (d, J = 8.8 Hz, 2H, 
aromatic CH), 9.55 (s, 1H, NH), 10.25 (s, 1H, NHCO). Anal. (C21H21N5O2 · 0.5 H2O) C, H, N. 
N-(5-Methyl-7-phenyl-4,7-dihydro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)-4-nitrobenzamide (23). 
Yield, 60%. Light yellow crystals, mp 272-274 °C; 1H NMR (DMSO-d6)  1.80 (s, 3H, CH3), 4.50 
and 5.90 (s, each 1H, CH), 7.15-7.30 (m, 5H, aromatic CH), 8.05 and 8.25 (d, J = 8.8 Hz, each 2H, 
aromatic CH), 9.55 (s, 1H, NH), 10.85 (s, 1H, NHCO). Anal. (C19H16N6O3 · 0.4 H2O) C, H, N.  
4-Chloro-N-(5-methyl-7-phenyl-4,7-dihydro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)benzamide 
(24). Yield, 31%. White crystals, mp 254-256 °C; 1H NMR (DMSO-d6)  1.80 (s, 3H, CH3), 4.50 
and 5.90 (s, each 1H, CH), 7.10-7.30 (m, 5H, aromatic CH), 7.45 and 7.80 (d, J = 8.8 Hz, each 2H, 
aromatic CH), 9.55 (s, 1H, NH), 10.55 (s, 1H, NHCO). Anal. (C19H16ClN5O · 0.2 H2O) C, H, N.  
N-(5-Methyl-7-phenyl-4,7-dihydro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)-2-naphthamide (25). 
Yield, 42%. Pink crystals, mp 230 °C (dec.); 1H NMR (DMSO-d6)  1.80 (s, 3H, CH3), 4.50 and 
5.90 (s, each 1H, CH), 7.20-7.30 (m, 5H, aromatic CH), 7.50-7.55 (m, 2H, aromatic CH), 7.90-8.00 
(m, 4H, aromatic CH), 8.45-8.50 (m, 1H, aromatic CH), 9.55 (s, 1H, NH), 10.50 (s, 1H, NHCO). 
Anal. (C23H19N5O · 0.3 H2O) C, H, N.  
N-(5-Methyl-7-phenyl-4,7-dihydro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)benzamide (26). Yield, 
18%. Light brown crystals, mp 257 °C (dec.); 1H NMR (DMSO-d6)  1.80 (s, 3H, CH3), 4.50 and 
5.90 (s, each 1H, CH), 7.20-7.50 (m, 8H, aromatic CH), 7.75 and 7.80 (m, 2H aromatic CH), 9.55 
(s, 1H, NH), 10.50 (s, 1H, NHCO). Anal. (C19H17N5O · 0.2 H2O) C, H, N.  
N-(5-Methyl-7-phenyl-4,7-dihydro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)-3-phenylpropanamide 
(27). Yield, 9%. White crystals, mp 169-171 °C; 1H NMR (DMSO-d6)  1.80 (s, 3H, CH3), 2.50 
and 2.75 (t, J = 7.2 Hz, each 2H, CH2), 4.50 and 5.90 (s, each 1H, CH), 7.00-7.25 (m, 10H, 
aromatic CH), 9.55 (s, 1H, NH), 10.00 (s, 1H, NHCO). Anal. (C21H21N5O · 0.3 H2O) C, H, N.  
Compounds 28-30 were prepared starting from synthone 4128 through Method A and purified by 
flash chromatography eluting with CHCl3/MeOH (98:2). 
N-(5-Methyl-7-phenyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)benzamide (28). Yield, 19%. White 
crystals, mp 183-185 °C 1H NMR (DMSO-d6)  2.75 (s, 3H, CH3), 7.05 (s, 1H, H-6), 7.40-7.55 (m, 
6H, aromatic CH), 8.00 (d, J = 7.0 Hz, 2H, aromatic CH), 8.15-8.20 (m, 2H, aromatic CH), 9.75 (s, 
1H, NHCO); 13C NMR (CDCl3)  25.1, 109.4, 127.9, 128.6, 128.9, 129.3, 129.6, 131.8, 132.2, 
133.7, 146.8, 154.9, 160.0, 164.7, 165.0. HRMS: m/z calcd for C19H15N5O 330.1310 (M + H
+), 
found 330.1359. 
4-Methoxy-N-(5-methyl-7-phenyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)benzamide (29). Yield, 
68%. White crystals, mp 190-192 °C; 1H NMR (DMSO-d6)  2.75 (s, 3H, CH3), 3.80 (s, 3H, 
OCH3), 6.90 (d, J = 8.8 Hz, 2H, aromatic CH) 7.05 (s, 1H, H-6), 7.50-7.55 (m, 3H, aromatic CH), 
7.95 (d, J = 8.8 Hz, 2H, aromatic CH), 8.15-8.20 (m, 2H, aromatic CH), 9.25 (s, 1H, NHCO). Anal. 
(C20H17N5O2) C, H, N.  
N-(5-Methyl-7-phenyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)-4-propoxybenzamide (30). Yield, 
27%. White crystals, mp 180-182 °C; 1H NMR (DMSO-d6)  1.05 (t, J = 7.0 Hz, 3H, CH2CH3), 
1.90 (sex, J = 7.0 Hz, 2H, CH2CH3), 2.75 (s, 3H, CH3), 4.00 (t, J = 7.0 Hz, 2H, OCH2), 6.90 (d, J = 
8.8 Hz, 2H, aromatic CH) 7.05 (s, 1H, H-6), 7.55-7.65 (m, 3H, aromatic CH), 8.00 (d, J = 8.8 Hz, 
2H, aromatic CH), 8.20-8.25 (m, 2H, aromatic CH), 9.30 (bs, 1H, NHCO). Anal. (C22H21N5O2) C, 
H, N.  
Compounds 31-33 were prepared starting from synthone 42 through Method A and purified by 
flash chromatography eluting with CHCl3/MeOH (98:2).  
N-(7-Methyl-5-phenyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)benzamide (31). Yield, 23%. Light 
brown crystals, mp 217 °C (dec.); 1H NMR (DMSO-d6)  2.75 (s, 3H, CH3), 7.50-7.65 (m, 6H, 
aromatic CH), 7.90 (s, 1H, H-6), 8.05 (d, J = 7.0 Hz, 2H, aromatic CH), 8.25-8.30 (m, 2H, aromatic 
CH), 11.50 (s, 1H, NHCO); 13C NMR (DMSO-d6)  17.5, 107.3, 127.8, 128.5, 128.8, 129.5, 131.5, 
132.6, 134.1, 136.6, 148.2, 154.5, 159.8, 160.8, 165.3. HRMS: m/z calcd for C19H15N5O 330.1310 
(M + H+), found 330.1355. 
4-Methoxy-N-(7-methyl-5-phenyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)benzamide (32). Yield, 
42%. White crystals, mp 210-213 °C; 1H NMR (DMSO-d6)  2.80 (s, 3H, CH3), 3.85 (s, 3H, 
OCH3), 7.05 (d, J = 8.4 Hz, 2H, aromatic CH) 7.55-7.60 (m, 3H, aromatic CH), 7.90 (s, 1H, H-6), 
8.05 (d, J = 8.4 Hz, 2H, aromatic CH), 8.25-8.30 (m, 2H, aromatic CH), 11.25 (s, 1H, NHCO). 
Anal. (C20H17N5O2) C, H, N.  
N-(7-Methyl-5-phenyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)-4-propoxybenzamide (33). Yield, 
35%. White crystals, mp 184-186 °C; 1H NMR (DMSO-d6)  1.00 (t, J = 7.0 Hz, 3H, CH2CH3), 
1.75 (sex, J = 7.0 Hz, 2H, CH2CH3), 2.85 (s, 3H, CH3), 4.00 (t, J = 7.0 Hz, 2H, OCH2), 7.05 (d, J = 
8.8 Hz, 2H, aromatic CH) 7.55-7.60 (m, 3H, aromatic CH), 7.90 (s, 1H, H-6), 8.05 (d, J = 8.8 Hz, 
2H, aromatic CH), 8.25-8.30 (m, 2H, aromatic CH), 11.25 (s, 1H, NHCO). Anal. (C22H21N5O2) C, 
H, N.  
General procedure for carbodiimide formation (Method B). To a solution of the suitable 
carboxylic acid (1.0 equiv) in well dry CH2Cl2, oxalyl chloride (3 equiv) was added and after 30 
min DMF (2 drops) was added. After 2 h, the reaction mixture was evaporated to dryness to give a 
residue that was dissolved in well dry CH2Cl2 and added of the appropriate aniline (1.0 equiv) and 
DIPEA (1.0 equiv). After 1 h, the reaction mixture was evaporated to dryness to give a residue that 
was treated with ice/water to give a solid that was filtered and purified as described below.  
Compounds 34 and 36 were prepared starting from synthone 45 through Method B and purified by 
flash chromatography eluting with CHCl3/MeOH (98:2) and then by crystallization by EtOH/DMF 
mixture. 
7-Methyl-N,5-diphenyl[1,2,4]triazolo[1,5-a]pyrimidine-2-carboxamide (34). Yield, 42%. 
Yellow crystals, mp 186-188 °C; 1H NMR (CDCl3)  2.85 (s, 3H, CH3), 7.15-7.20 (m, 2H, H-6 and 
aromatic CH), 7.40 (t, J = 7.9 Hz, 2H, aromatic CH), 7.60-7.65 (m, 3H, aromatic CH), 7.80 (d, J = 
7.9 Hz, 2H, aromatic CH), 8.15-8.20 (m, 2H, aromatic CH), 9.00 (s, 1H, NHCO). HRMS: m/z calcd 
for C19H15N5O 330.1310 (M + H
+), found 330.1358. Anal. (C19H15N5O) C, H, N.  
5-Methyl-N,7-diphenyl[1,2,4]triazolo[1,5-a]pyrimidine-2-carboxamide (35). Yield, 39%. White 
crystals, mp 242-245 °C; 1H NMR (CDCl3)  3.00 (s, 3H, CH3), 7.20 (t, J = 7.3 Hz, 1H, aromatic 
CH), 7.40 (t, J = 7.9 Hz, 2H, aromatic CH), 7.60-7.65 (m, 4H, H-6 and aromatic CH), 7.85 (d, J = 
7.9 Hz, 2H, aromatic CH), 8.25-8.30 (m, 2H, aromatic CH), 9.50 (s, 1H, NHCO). HRMS: m/z calcd 
for C19H15N5O 330.1310 (M + H
+), found 330.1360. Anal. (C19H15N5O) C, H, N.  
N-[3-(aminocarbonyl)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thien-2-yl]-7-methyl-5-
phenyl[1,2,4]triazolo[1,5-a]pyrimidine-2-carboxamide (36). Yield, 30%. Yellow crystals, mp 
288 °C (dec.); 1H NMR (DMSO-d6)  1.50-1.65 (m, 4H, cycloheptane CH2), 1.75-1.80, (m, 2H, 
cycloheptane CH2), 2.60-2.70 (m, 5H, cycloheptane CH2 and CH3), 2.75-2.80 (m, 2H, cycloheptane 
CH2), 7.45-7.60 (m, 6H, aromatic CH, NH2, and H-6), 8.20-8.25 (m, 2H, aromatic CH), 12.00 (s, 
1H, NHCO); 13C NMR (DMSO-d6)  25.34, 27.5, 27.9, 28.6, 28.7, 31.9, 112.3, 122.2, 129.1, 129.7, 
130.0, 131.7, 132.2, 135.6, 136.7, 147.1, 155.5, 155.9, 157.5, 167.4, 167.7. HRMS: m/z calcd for 
C23H22N6O2S 447.1558 (M + H
+), found 447.1611. Anal. (C23H22N6O2S) C, H, N.  
N-[3-(Aminocarbonyl)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thien-2-yl]-5-methyl-7-
phenyl[1,2,4]triazolo[1,5-a]pyrimidine-2-carboxamide (37). Yield, 25%. Orange crystals, mp 
313 °C (dec.); 1H NMR (DMSO-d6)  1.50-1.65 (m, 4H, cycloheptane CH2), 1.75-1.80, 2.70-2.75, 
and 2.80-2.85 (m, each 2H, cycloheptane CH2), 2.90 (s, 3H, CH3), 7.45-7.60 (m, 5H, aromatic CH 
and NH2), 8.05 (s, 1H, H-6), 8.25-8.30 (m, 2H, aromatic CH), 12.00 (s, 1H, NHCO); 
13C NMR 
(DMSO-d6)  17.4, 27.5, 27.9, 28.6, 28.7, 32.0, 109.2, 122.1, 128.1, 129.6, 131.8, 132.1, 135.6, 
136.2, 136.7, 149.7, 155.2, 155.5, 157.9, 161.9, 167.7. HRMS: m/z calcd for C23H22N6O2S 
447.1558 (M + H+), found 447.1601. Anal. (C23H22N6O2S) C, H, N.  
7-Methyl-5-phenyl[1,2,4]triazolo[1,5-a]pyrimidin-2-amine (42). To a solution of 3,5-diamino-
1,2,4-triazole (0.1 g, 0.001 mmol) in DMF (5 mL) at reflux, phenyl 1-propenyl ketone (0.14 mL, 
0.001 mmol) was added and the reaction mixture was maintained at reflux for 30 min. After 
cooling, the mixture was evaporated to dryness, obtaining a residue that was purified by flash 
chromatography eluting with CH2Cl2/MeOH (98:2), to give 42 (0.1 g, 44%); mp 225-227 °C; 
1H 
NMR (DMSO-d6)  2.60 (s, 3H, CH3), 6.35 (s, 2H, NH2), 7.45-7.50 (m, 3H, aromatic CH), 7.05 (s, 
1H, H-6), 8.05-8.15 (m, 2H, aromatic CH); 13C NMR (DMSO-d6)  17.4, 105.4, 127.4, 129.3, 
130.9, 137.0, 146.1, 155.1, 157.4, 167.3.  
Ethyl 5-methyl-7-phenyl-4,7-dihydro[1,2,4]triazolo[1,5-a]pyrimidine-2-carboxylate (43). The 
title compound was prepared starting from ethyl 5-amino-1,2,4-triazole-3-carboxylate29 and 
following the same procedure as used for the synthesis of 42 (2 h) using benzylideneacetone. After 
cooling, the reaction mixture was poured into ice/water obtaining a precipitate that was filtered and 
washed with Et2O, to give 43 in 29% yield, which was used without further purification; 
1H NMR 
(DMSO-d6)  1.20 (t, J = 7.1 Hz, 3H, CH2CH3), 1.80 (s, 3H, CH3), 4.20 (q, J = 7.1 Hz, 2H, 
CH2CH3), 4.55 and 6.00 (bs, each 1H, CH), 7.20-7.30 (m, 5H, aromatic CH), 9.75 (s, 1H, NH). 
Ethyl 5-methyl-7-phenyl[1,2,4]triazolo[1,5-a]pyrimidine-2-carboxylate (44). To a suspension of 
43 (1.4 g, 4.92 mmol) in EtOH (30 mL), NaOAc (0.59 g, 7.18 mmol) was added and the reaction 
mixture was heated at 40-50 °C. Then, NBS (0.87 g, 4.88 mmol) was added and the reaction 
mixture was refluxed for 30 min. After cooling, the reaction mixture was poured into ice/water 
obtaining a precipitate that was filtered and purified by flash chromatography eluting with 
CH2Cl2/MeOH (98:2), to give 44 (0.45 g, 33%); mp 174-176 °C; 
1H NMR (CDCl3)  1.45 (t, J = 
7.1 Hz, 3H, CH2CH3), 2.75 (s, 3H, CH3), 4.50 (q, J = 7.1 Hz, 2H, CH2CH3), 7.15 (s, 1H, H-6), 7.55-
7.65 (m, 3H, aromatic CH), 8.05-8.10 (m, 2H, aromatic CH).  
5-Methyl-7-phenyl[1,2,4]triazolo[1,5-a]pyrimidine-2-carboxylic acid (45). A mixture of 44 
(0.45 g, 1.59 mmol) and NaOH (0.079 g, 1.99 mmol) in MeOH (10 mL) was refluxed for 30 min. 
After cooling, the reaction mixture was poured into ice/water and acidified with 2N HCl obtaining a 
precipitate that was filtered. The filtrate was extracted with EtOAc and the organic layers were 
evaporated to dryness obtaining a residue that was treated with Et2O and filtered, to give 45 (0.13 g, 
32%); mp 172-174 °C; 1H NMR (DMSO-d6)  2.70 (s, 3H, CH3), 7.55-7.60 (m, 4H, H-6 and 
aromatic CH), 8.05-8.10 (m, 2H, aromatic CH).  
Ethyl 7-methyl-5-phenyl[1,2,4]triazolo[1,5-a]pyrimidine-2-carboxylate (46). The title 
compound was prepared starting from ethyl 5-amino-1,2,4-triazole-3-carboxylate20 following the 
same procedure as used for the synthesis of 42 (1 h). After cooling, the reaction mixture was poured 
into ice/water and extracted with EtOAc. The organic layers were evaporated to dryness obtaining a 
residue that was treated with Et2O, to give 46 in 11% yield; mp 170-172 °C; 
1H NMR (DMSO-d6) 
1.30 (t, J = 7.1 Hz, 3H, CH2CH3), 2.80 (s, 3H, CH3), 4.50 (q, J = 7.1 Hz, 2H, CH2CH3), 7.50-7.65 
(m, 3H, aromatic CH), 8.05 (s, 1H, H-6), 8.15-8.25 (m, 2H, aromatic CH).  
7-Methyl-5-phenyl[1,2,4]triazolo[1,5-a]pyrimidine-2-carboxylic acid (47). The title compound 
was prepared from 46 following the same procedure as used for the synthesis of 45 (2 h). After 
cooling, the reaction mixture was evaporated to dryness obtaining a residue that was treated with 
ice/water and acidified with 2N HCl obtaining a precipitate that was filtered and washed with Et2O, 
to give 47 in 87% yield; mp 168-169 °C; 1H NMR (DMSO-d6)  2.90 (s, 3H, CH3), 7.50-7.60 (m, 
3H, aromatic CH), 8.05 (s, 1H, H-6), 8.20-8.25 (m, 2H, aromatic CH).  
Compounds 35 and 37 were prepared starting from synthone 47 through Method B and purified by 
flash chromatography eluting with CHCl3/MeOH (98:2) and then by crystallization by EtOH/DMF 
mixture. 
Biology  
Compounds and peptide. RBV (1-D-ribofuranosyl-1,2,4-triazole-3-carboxamide) was obtained 
from Roche. Each test compound was dissolved in DMSO 100%. The PB1(1–15)–Tat peptide was 
synthesized and purified by the Peptide Facility of CRIBI Biotechnology Center (University of 
Padua, Padua, Italy). This peptide contains the first 15 N-terminal amino acids of PB1 protein 
conjugated to the C-terminal sequence of HIV Tat protein (amino acids 47−59), which allows 
intracellular delivery.44 
Plasmids. Plasmids pcDNA-PB1, pcDNA-PB2, pcDNA-PA, and pcDNA-NP, containing cDNA 
copies of the influenza A/PR/8/34 virus PB1, PB2, PA, and NP genes, respectively, were created as 
described elsewhere34 and kindly provided by P. Digard (Roslin Institute, University of Edinburgh, 
United Kingdom). Plasmid pPolI-Flu-ffLuc, which contains an influenza virus-based luciferase 
minireplicon vRNA under the control of the human RNA polymerase I promoter, was provided by 
L. Tiley (University of Cambridge, United Kingdom). Plasmid pRL-SV40 expressing the Renilla 
luciferase was purchased from Promega. The pcDNA-PA-GFP plasmid, which encodes a PA-GFP 
fusion protein was kindly provided by E. Fodor (University of Oxford, United Kingdom). 
Cells and Virus. Human Embryonic Kidney (HEK) 293T and Mardin-Darby canine kidney  
(MDCK) cells were grown in Dulbecco’s modified Eagle’s medium (DMEM, Life Biotechnologies) 
supplemented with 10% (v/v) fetal bovine serum (FBS, Life Technologies) and antibiotics (100 
U/mL penicillin and 100 µg/mL streptomycin, Life Technologies). The cells were maintained at 37 
°C in a humidified atmosphere with 5% CO2. Influenza A/PR/8/34 virus (H1N1, Cambridge 
lineage) was obtained from P. Digard (Roslin Institute, University of Edinburgh, United Kingdom). 
The FluA strains A/Wisconsin/67/05 and A/Solomon Island/3/06 and the FluB strains 
B/Malaysia/2506/4 and B/Bangladesh/333/07 were provided by R. Cusinato (Clinical Microbiology 
and Virology Unit, Padua University Hospital, Padua, Italy). The clinical isolate A/Parma/24/09 
was kindly provided by I. Donatelli (Istituto Superiore di Sanità, Rome, Italy). Influenza B/Lee/40 
virus was obtained from W. S. Barclay (Imperial College, London, United Kingdom). All influenza 
viruses were propagated in MDCK cells. 
PA-PB1 interaction enzyme-linked immunosorbent assay (ELISA). The PA−PB1 interaction 
was detected by a procedure already described.9 Briefly, microtiter plates (Nuova Aptca) were 
coated with 400 ng of 6His-PA(239−716) for 3 h at 37 °C and then blocked with 2% BSA (Sigma) in 
PBS for 1 h at 37 °C. The 6His-PA(239−716) protein was expressed in E. coli strain BL21(DE3)pLysS 
and purified as described.9 After washing, 200 ng of GST-PB1(1−25), or of GST alone as a control, 
in the absence or the presence of test compounds at various concentrations (10, 50, 100, 200 μM), 
were added and incubated O/N at room temperature. Escherichia coli-expressed, purified GST and 
GST-PB1(1−25) proteins were obtained as previously described.
9 After washing, the interaction 
between 6His-PA(239−716) and GST-PB1(1−25) was detected with an anti-GST monoclonal 
antibody conjugated to horseradish peroxidase (HRP) (GenScript). Following washes, the substrate 
3,3′,5,5′tetramethylbenzidine (TMB, KPL) was added and absorbance was measured at 450 nm by 
an ELISA plate reader (Tecan Sunrise™). Values obtained from the samples treated with only 
DMSO were used to set as 100% of PA−PB1 interaction.  
Cytotoxicity assay. Cytotoxicity of compounds was tested in MDCK and HEK 293T cells by the 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) method, as previously 
reported.9  
Plaque reduction assay (PRA). The experiments were carried out as previously described.9 
Briefly, confluent monolayers of MDCK cells were infected with FluA or FluB virus at 40 
PFU/well in DMEM supplemented with 1 μg/mL of TPCK-treated trypsin (Worthington 
Biochemical Corporation) and 0.14% BSA and incubated for 1 h at 37°C. The influenza viruses 
infection was performed in the presence of different concentrations of test compounds or solvent 
(DMSO) as a control. Serum-free medium containing 1 μg/mL of TPCK-treated trypsin, 0.14% 
BSA, 1.2% Avicel, and DMSO or test compounds at the indicated concentrations was added after 1 
h of virus adsorption. After 48 h of incubation, cells were fixed with 4% formaldehyde and stained 
with 0.1% toluidine blue. Viral plaques were counted, and the mean plaque number in the DMSO-
treated control was set at 100%. 
Minireplicon assay. HEK 293T cells were seeded at 105 per well on 24-well plates. After 24 h, 
cells were transfected, in the presence of test compounds at different concentrations or DMSO, with 
pcDNA-PB1, pcDNA-PB2, pcDNA-PA, pcDNA-NP plasmids (100 ng/well of each) along with 
pPolI-Flu-ffLuc plasmid (50 ng/well) as described elsewhere.9 In addition, a plasmid constitutively 
expressing Renilla luciferase, pRL-SV40 (50 ng/well), was included in the transfection mixture to 
normalize variations in transfection efficiency. After 4 h, the medium was replaced with fresh 
DMEM containing DMSO or test compounds. At 24 h post-transfection, cells were lysed, and the 
relative firefly and Renilla luciferase activities were determined using the Dual Luciferase Assay 
Kit from Promega and a luminescence counter (Victor X2, PerkinElmer). The luciferase activities 
of the samples treated with DMSO were set as 100%. 
Analysis of nuclear accumulation of the PA-PB1 complex in the presence of compound 36. 
HEK 293T cells were transiently transfected using the Arrest-IN™ (Biosystems) with pcDNA-PA-
GFP, pcDNA-PB1, and pcDNA-PB2 in the absence or the presence of compound 36 (50 M) or 
DMSO as a control. At 24 hr post-transfection, cells were fixed for 20 min with 4% formaldehyde 
in PBS. After permeabilization with 0.2 % Triton X-100 in PBS for 5 min at RT, cells were 
incubated for 20 min with TOTO-3 iodide (Molecular Probes) in PBS and 4% FBS, mounted using 
mounting fluid (70% glycerol in PBS), and imaged using a Leica TCS-NT/SP2 confocal 
microscope equipped with a 63X oil immersion objective. Images were digitally analyzed with 
Leica software. 
Preliminary ADME studies  
Metabolic stability. The selected substrates were incubated with human liver microsomes (HLM, 
0.5 mg protein/ml) (BD Biosciences) according to manufacturer’s recommendations with minor 
modification. In summary, substrates at 5 µM final concentration were pre-incubated in a shaking 
water bath for 5 min at 37 °C in 100 mM potassium phosphate buffer (pH 7.4) in a total volume of 
250 µL. Thus, 10 µL of a 1 mM NADPH aqueous solution were added to activate the enzymatic 
process. After incubation for 0 and 30 min, the addition of 250 µL of cold acetonitrile (containing 
0.6 μM labetalol as internal standard) was used to terminate the reaction. Proteins were precipitated 
by centrifugation at 12,000 x g for 5 min at 4 °C, and aliquots of supernatants were analyzed by 
HPLC-MS/MS, on an Agilent 6550 UHD accurate mass Q-TOF LC/MSMS system (Agilent 
Technologies, Palo Alto, CA) governed by Agilent MassHunter software (B.05.01 version). The 
system consists of a binary pump, autosampler, thermostated column compartment, DAD detector, 
source and Q-TOF spectrometer. Chromatographic separation of the metabolites (Agilent 1290 
UHPLC system) was performed with Agilent RRHD 1.7 μ -C18, 100 x 2.1 mm (Phenomenex USA) 
at a constant temperature of 40 °C. The mobile phases consisted of A: H2O/0.1% formic acid and B: 
acetonitrile/0.1% formic acid at the flow of 0.45 mL/min with the following gradient: Time 0 min, 
B 10%; Time 6 min, B 100%. The DAD Detector stored all the acquired spectra in the 190-640 nm 
range (2 nm spectrum step). The ion source was an Agilent Dual JetStream operating under positive 
ionization mode (4000 V), with as nitrogen the desolvating gas (290 °C, 12 L/min, 35 psig). The 
fragmentor was set to 375 V, the skimmer to 65 V, and the octrapole RF to 750 V. The 
spectrometric data were collected in AutoMS/MS mode in the 100-1000 mass range, with 3 
scans/sec at Collision Energy of 30 V. The TOF operated at 2 GHz. 
Permeability assay. The PAMPA (Parallel Artificial Membrane Permeation Assay) method46 was 
used to study permeability of compounds 8, 16, 31, 36, and 37. In a PAMPA assay drugs permeate 
by passive diffusion from the donor compartment (320 µL, Roche Teflon plate), to the acceptor 
compartment (280 µl, Millipore MAIPN4550), where the acceptor and the donor compartments are 
separated by a phospholipid coated filter (4.5 µL, Millipore MAIPN4550). Donor buffer: 0.05 M 
MOPSO at pH 6.5 + 0.5% (w/v) Glycocholic acid. Acceptor buffer: 0.05 M MOPSO at pH 6.5. 
Membrane: 10% (w/v) Egg Lecithin in Dodecane + 0.5% (w/v) Cholesterol. Permeation time was 
18 h. The permeation constant, Peff [10
-6 x cm/s], and the sample distribution can be retrieved by 
UV analytics (SpectraMax Plus 384 Absorbance Microplate Reader, Molecular Devices) of donor 
(tstart), donor (tend) and acceptor (tend) using the pION PAMPA Evolution software. According to this 
method, low permeability is expected when Peff < 0.2 x 10
-6 cm/s and Membrane% < 20%, where 
Peff represents the effective permeability and Membrane% represents the percentage of compounds 
trapped into the membrane. When one or both parameters are above the cut-off then a medium to 
high permeability is expected (compound 8: Peff = 3.52 x 10
-6 cm/s and Membrane% = 57%; 
compound 16: Peff = 2.93 x 10
-6 cm/s and Membrane% = 41%; compound 31: Peff = 5.49 x 10
-6 cm/s 
and Membrane% = 2%; compound 36: Peff = 0.61 x 10
-6 cm/s and Membrane% = 45%; compound 
37: undetected; compound 7: Peff = 0.00 x 10
-6 cm/s and Membrane% = 99%; compound 10: Peff = 
0.00 x 10-6 cm/s and Membrane% = 98%). 
Equilibrium solubility in aqueous media. An accurately weighted amount of compound (about 1 
mg) as dry powder was placed in a glass tube and 330 µL of 0.15 M Phosphate buffer at pH 7.4 
were added. Thus, the sample was ultrasonicated for 1 hour, shaken at room temperature for 2 hours 
(Branson 1210, Branson Ultrasonics, Danbury, CT) and let stand to equilibrate overnight. The next 
day, the pH of the sample was checked and the solution was filtered using a MultiScreenHTS-PCF 
filter (Millipore, Darmstadt, Germany). Aliquots of the filtrate were used to generate three different 
samples (undiluted, diluted as 1:10 and as 1:100) by dilution with the same buffer. Compound 
calibration curves were generated from standard 1 mg/mL DMSO solutions diluted in buffer. 
Calibration standards and samples were then analyzed by LC-UV.MS using an Agilent 1260 
Infinity HPLC-MS system (Agilent Technologies, Santa Clara, CA) equipped with a DAD detector 
and an API single quadruple mass spectrometer (Agilent 6140, Santa Clara, CA). A Kinetex XB 2.6 
µm, 2.1 x 50 mm analytical column (Phenomenex, Torrance, CA) operating at 60 °C was used. The 
mobile phase consisted of A (water) and B (acetonitrile), both containing 0.1 %/vol formic acid. 
The gradient elution was performed with a flow rate of 1.5 mL/min using a generic fast gradient. 
After detection with DAD, the eluent entered the electrospray system using the following source 
settings: capillary voltage + 3.5 kV, drying gas flow (N2) 13 L/min, nebulizer pressure 60 sig, 
drying gas temperature 350 °C. The integral of the pseudo molecular ion intensity, [M+H]+, was 
acquired in single reaction monitoring mode (SRM). 
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Table 1.  Structure and Biological Activity of the Compounds Synthesized in This Study. 
     
Cytotoxicity  
(MTT Assay) 
Compd R 
ELISA 
PA-PB1  
Interaction Assay 
IC50, µM
a 
PRA  
in MDCK 
cells 
EC50, µM
b 
HEK 293T 
cells 
CC50, µM
c 
MDCK cells 
CC50, µM
c 
8 
 
153 ± 35 >100 >250 240 ± 19 
11 
 
>200 >100 240 ± 27 >250 
12 
 
175 ± 17 >100 230 ± 17 >250 
13 
 
138 ± 17 >100 190 ± 11 >250 
14 
 
156 ± 6 >100 220 ± 13 >250 
15 
 
185 ± 12 >100 >250 >250 
16 
 
40 ± 3 47 ± 5 >250 230 ± 22 
17 
 
37 ± 4 100 ± 16 >250 196 ± 15 
18 
 
48 ± 7 100 ± 7 >250 >250 
19 
 
156 ± 18 59 ± 3 73 ± 6 180 ± 15 
20 
 
75 ± 5 >100 >250 >250 
21 
 
>200 28 ± 2 155 ± 16 193 ± 21 
22 
 
139 ± 23 100 ± 8 237 ± 14 >250 
23 
 
75 ± 5 >100 >250 >250 
24 
 
95 ± 13 >100 >250 >250 
25 
 
>200 41 ± 1 154 ± 15 115 ± 10 
26 
 
100 ± 10 100 ± 13 >250 >250 
27 
 
100 ± 20 >100 223 ± 19 >250 
 
28 
 
>200 >100 >250 >250 
29 
 
>200 86 ± 4  187 ± 14 >250 
30 
 
>200 >100 95 ± 6 72 ± 9 
 
31 
 
26 ± 5 25 ± 1  196 ± 11 >250 
32 
 
150 ± 11 >100 109 ± 16 >250 
33 
 
158 ± 14 >100 52  ± 2 247  ± 3 
 34 
 
160 ± 11  42 ± 5 110 ± 15 >250 
36 
 
1.1 ± 0.3 21 ± 4 >250 >250 
 
35 
 
128 ± 15 49 ± 2 >250 >250 
37 
 
28 ± 1 8 ± 2 >250 >250 
RBV   10 ± 2 >250 >250 
Tat-PB11-15 
peptide 
 35 ± 3 40 ± 5 >100 >100 
a Activity of the compounds in ELISA PA-PB1 interaction assays. The IC50 value represents the compound 
concentration that reduces by 50% the interaction between PA and PB1. b Activity of the compounds in plaque 
reduction assays with the FluA A/PR/8/34 strain. The EC50 value represents the compound concentration that inhibits 
50% of plaque formation. c Activity of the compounds in MTT assays. The CC50 value represents the compound 
concentration that causes a decrease of cell viability of 50%. All the reported values represent the means ± SD of data 
derived from at least three independent experiments in duplicate. 
 
 
 
Table 2. Activity of Selected Compounds Against 
FluA RNA Polymerase Activity. 
Compound 
FluA Minireplicon Assay 
(EC50, µM )a 
16 38 ± 2 
31 35 ± 7 
36 12 ± 1 
37 16 ± 5 
RBV 18 ± 4 
a The EC50 value represents the compound 
concentration that reduces by 50% the activity of FluA 
virus RNA polymerase in 293T cells. All data shown 
represent the means ± SD of data derived from at least 
three independent experiments in duplicate. 
 
Table 3. Activity of Selected Compounds Against a Panel of FluA and FluB Strains. 
Virus strain 
Compound 
PRA (EC50, µM )a 
16 31 36 37 
A/PR/8/34 (H1N1) 47 ± 5 25 ± 1 21 ± 4 8 ± 2 
A/Solomon Island/3/06 (H1N1) 27 ± 3 27 ± 2 23 ± 4 16 ± 4 
A/Parma/24/09 (H1N1) 
(Oseltamivir-resistant) 
49 ± 7 25 ± 3 25 ± 2 5 ± 1 
A/Wisconsin/67/05 (H3N2) 37 ± 6 24 ± 2 7 ± 1 14 ± 3 
B/Lee/40 51 ± 6 25 ± 2 24 ± 4 5 ± 1 
B/Malaysia/2506/04 32 ± 2 36 ± 3 17 ± 2 11 ± 3 
B/Bangladesh/333/07 27 ± 4 34 ± 2 11 ± 1 12 ± 2 
a The EC50 value represents the compound concentration that inhibits 50% of plaque formation. All 
data shown represent the means ± SD of data derived from at least three independent experiments. 
 
 
 
Figure legends 
Figure 1. Small molecules RNA-dependent RNA polymerase PA-PB1 interaction inhibitors. For 
the definition of IC50, EC50, and CC50 values, see Table 1.  
Figure 2. Pharmacophore model for PA-PB1 inhibitors (A) and alignment of 28 (B) and 31 (C) on 
it using FLAP. Color code for the pharmacophore points: green = hydrophobic; red = H-bond 
acceptor; blue = H-bond donor. 
Figure 3. Alignment of 36 (A) and 37 (B) to the pharmacophore model.  
Figure 4. FLAP binding poses for compounds 26 (A) and 28 (B). A detail of the interaction of the 
two compounds with W706 is also reported (C). The GRID hydrophobic regions (green) generated 
using the FLAP software are displayed,29 together with some of the PA key residues located in the 
cavity. 
Figure 5. FLAP binding poses for compounds 36 (B, D) and 37 (A, C). Two different orientations 
in the PA cavity are reported for each compound, to better visualize the hypothesized interactions. 
Figure 6. Effects of compound 36 on PA-PB1 interaction in cells. HEK 293T cells were transfected 
with plasmids expressing PB1, PB2, and a PA-GFP fusion protein in the absence or the presence of 
compound 36 or DMSO as a control. Non-transfected cells (None) and cells transfected with the 
PA-GFP-expressing plasmid alone served as negative controls. At 24 hr post-transfection, cells 
were examined by confocal laser scanning microscopy. Individual blue (TOTO-3 iodide) and green 
(GFP) channels are shown, with merged images on the right.  
 
Scheme Footnotes 
Scheme 1a  
a Reagents and conditions: (i) DMF, reflux; (ii) pyridine; (iii) DMF, Ac2O, reflux; (iv) AcONa, 
NBS, EtOH, reflux; (v) 12N HCl, EtOH, reflux. 
 
Scheme 2a 
a Reagents and conditions: (i) DMF, reflux; (ii) AcONa, NBS, EtOH, reflux; (iii) NaOH, MeOH, 
reflux; (iv) 1) oxalyl chloride, CH2Cl2, DMF; 2) R’NH2, CH2Cl2, DIPEA. 
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IC50 = 35 µM 
EC50 = 1 µM 
CC50 = 40 µM  
 
IC50 = 20.3 µM 
EC50 = 14.5 µM 
CC50 > 250 µM  
 
EC50 = 39 µM EC50 = 31 µM 
IC50 = 30.4 µM 
EC50 = 12.2 µM 
CC50 > 1000 µM  
IC50 = 25.4 µM 
EC50 = 75.5 µM 
CC50 > 1000 µM  
 
IC50 = 90.7 µM 
EC50 > 100 µM 
CC50 > 250 µM  
 
IC50 = 170.6 µM 
EC50 > 100 µM 
CC50 > 250 µM  
 
HTS Serendipity 
IC50 = 7.5 µM 
EC50 = 23.7 µM 
CC50 > 250 µM  
 
IC50 = 32 µM 
EC50 = 18 µM 
CC50 > 250 µM  
 
First Round of Optimization 
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